Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database

The treatment of multiple myeloma has dramatically improved due to the availability of novel therapies that are highly effective and are quickly moving into first-line therapy. The Canadian Agency for Drugs and Technologies in Health (CADTH) recently recommended that patients who receive daratumumab...

Descripció completa

Dades bibliogràfiques

Autors principals:	Arleigh McCurdy, Christopher P. Venner, Esther Masih-Khan, Martha Louzada, Richard LeBlanc, Michael Sebag, Kevin Song, Victor H. Jimenez-Zepeda, Rami Kotb, Moustafa Kardjadj, Hira Mian, Darrell White, Julie Stakiw, Muhammad Aslam, Anthony Reiman, Engin Gul, Donna Reece
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2022-03-01
Col·lecció:	Current Oncology
Matèries:	multiple myeloma relapsed/refractory pomalidomide carfilzomib sequence
Accés en línia:	https://www.mdpi.com/1718-7729/29/3/132
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!